Jennifer A Schrack1, Keri N Althoff, Lisa P Jacobson, Kristine M Erlandson, Beth D Jamieson, Susan L Koletar, John Phair, Luigi Ferrucci, Todd T Brown, Joseph B Margolick. 1. *Department of Epidemiology, Johns Hopkins Bloomberg, School of Public Health, Baltimore, Maryland; †Department of Medicine, University of Colorado School of Medicine, Denver Colorado; ‡Department of Medicine, Hemtaology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California; §Division of Infectious Disease, Department of Internal Medicine, Ohio State University, Columbus, Ohio; ‖Translational Gerontology Branch, Intramural Research Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; ¶Division of Endocrineology and Metabolism, Internal Medicine, National Institute on Aging, National Institutes of Health, Baltimore, Maryland; and #Department of Molecular Microbiology and Immunology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Gait speed predicts functional decline, disability, and death and is considered a biomarker of biological aging. Changes in gait speed in persons aging with HIV may provide an important method of gauging health and longevity in an under assessed population. The objective of this study was to evaluate and quantify the rate of gait speed decline in HIV-infected (HIV⁺) men compared with HIV-uninfected (HIV⁻) men. METHODS: The study was nested in the Multicenter AIDS Cohort Study. The primary outcome was usual gait speed in meters per second measured between 2007 and 2013. Differences in the rate of gait speed decline and the incidence of clinically slow gait (<1.0 m/s) were assessed using multivariate linear regression models and Cox proportional hazards models, respectively. RESULTS: A total of 2025 men (973 HIV⁺ and 1052 HIV⁻) aged 40 years and older contributed 21,187 person-visits (9955 HIV⁺ and 11,232 HIV⁻) to the analysis. Average gait speeds at the age 50 years were 1.24 and 1.19 m/s in HIV⁻ and HIV⁺ men, respectively (P < 0.001). In fully adjusted models, gait speed decline averaged 0.009 m/s per year after age 50 years (P < 0.001); this decline was 0.025 m/s per year greater in HIV⁺ men (P < 0.001). Moreover, HIV⁺ men had a 57% greater risk of developing clinically slow gait (adjusted hazard ratio = 1.57, 95% confidence interval: 1.27 to 1.91). CONCLUSIONS: These findings indicate a faster rate of functional decline in HIV-infected men, suggesting greater risks of disability and death with advancing age.
BACKGROUND: Gait speed predicts functional decline, disability, and death and is considered a biomarker of biological aging. Changes in gait speed in persons aging with HIV may provide an important method of gauging health and longevity in an under assessed population. The objective of this study was to evaluate and quantify the rate of gait speed decline in HIV-infected (HIV⁺) men compared with HIV-uninfected (HIV⁻) men. METHODS: The study was nested in the Multicenter AIDS Cohort Study. The primary outcome was usual gait speed in meters per second measured between 2007 and 2013. Differences in the rate of gait speed decline and the incidence of clinically slow gait (<1.0 m/s) were assessed using multivariate linear regression models and Cox proportional hazards models, respectively. RESULTS: A total of 2025 men (973 HIV⁺ and 1052 HIV⁻) aged 40 years and older contributed 21,187 person-visits (9955 HIV⁺ and 11,232 HIV⁻) to the analysis. Average gait speeds at the age 50 years were 1.24 and 1.19 m/s in HIV⁻ and HIV⁺ men, respectively (P < 0.001). In fully adjusted models, gait speed decline averaged 0.009 m/s per year after age 50 years (P < 0.001); this decline was 0.025 m/s per year greater in HIV⁺ men (P < 0.001). Moreover, HIV⁺ men had a 57% greater risk of developing clinically slow gait (adjusted hazard ratio = 1.57, 95% confidence interval: 1.27 to 1.91). CONCLUSIONS: These findings indicate a faster rate of functional decline in HIV-infectedmen, suggesting greater risks of disability and death with advancing age.
Authors: J M Guralnik; L Ferrucci; C F Pieper; S G Leveille; K S Markides; G V Ostir; S Studenski; L F Berkman; R B Wallace Journal: J Gerontol A Biol Sci Med Sci Date: 2000-04 Impact factor: 6.053
Authors: Keri N Althoff; Lisa P Jacobson; Ross D Cranston; Roger Detels; John P Phair; Xiuhong Li; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-14 Impact factor: 6.053
Authors: Marco Pahor; Jack M Guralnik; Walter T Ambrosius; Steven Blair; Denise E Bonds; Timothy S Church; Mark A Espeland; Roger A Fielding; Thomas M Gill; Erik J Groessl; Abby C King; Stephen B Kritchevsky; Todd M Manini; Mary M McDermott; Michael E Miller; Anne B Newman; W Jack Rejeski; Kaycee M Sink; Jeff D Williamson Journal: JAMA Date: 2014-06-18 Impact factor: 56.272
Authors: L Ferrucci; B W Penninx; S G Leveille; M C Corti; M Pahor; R Wallace; T B Harris; R J Havlik; J M Guralnik Journal: J Am Geriatr Soc Date: 2000-09 Impact factor: 5.562
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Mehri S McKellar; Maragatha N Kuchibhatla; Kris Ann K Oursler; Stephen Crystal; Kathleen M Akgün; Kristina Crothers; Cynthia L Gibert; Karen Nieves-Lugo; Julie Womack; Janet P Tate; Gerda G Fillenbaum Journal: AIDS Res Hum Retroviruses Date: 2019-06-18 Impact factor: 2.205
Authors: Jeremy Walston; Thomas N Robinson; Susan Zieman; Frances McFarland; Christopher R Carpenter; Keri N Althoff; Melissa K Andrew; Caroline S Blaum; Patrick J Brown; Brian Buta; E Wesley Ely; Luigi Ferrucci; Kevin P High; Stephen B Kritchevsky; Kenneth Rockwood; Kenneth E Schmader; Felipe Sierra; Kaycee M Sink; Ravi Varadhan; Arti Hurria Journal: J Am Geriatr Soc Date: 2017-04-19 Impact factor: 5.562
Authors: Mary Clare Masters; Jeremiah Perez; Katherine Tassiopoulos; Adriana Andrade; Ronald Ellis; Jingyan Yang; Todd T Brown; Frank J Palella; Kristine M Erlandson Journal: AIDS Res Hum Retroviruses Date: 2019-09-30 Impact factor: 2.205
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Jennifer A Schrack; Lisa P Jacobson; Keri N Althoff; Kristine M Erlandson; Beth D Jamieson; Susan L Koletar; John Phair; Todd T Brown; Joseph B Margolick Journal: AIDS Date: 2016-11-13 Impact factor: 4.177
Authors: Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2020-09-23 Impact factor: 2.205